Browsing by Author Cariou, B

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2013Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseYue, Dennis; Bakris, George; Cariou, B; David Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, J; Central Clinical School: MedicineEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease, Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, vol.15, 5, 2013,pp 463-473
2014Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney diseaseYue, Dennis; Bakris, George; Cariou, B; David-Neto, Elias; et al, Various; Figueroa, K; Jiang, J; Law, Gordon; Nieto, J; Wajs, E; Yale, Jean-Francois; Central Clinical School: MedicineEfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease, Diabetes, Obesity and Metabolism, vol.16, 10, 2014,pp 1016-1027
2015PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialSullivan, David; Bridges, Ian; Burgess, Leslie; Cariou, B; Civeira, Fernando; Dufour, Robert; Gaudet, Daniel; Gouni-Berthold, Ioanna; Hovingh, G Kees; Langslet, Gisle; Olsson, Anders; Raal, Frederick J; Scott, Rob; Scott, Russell; Somaratne, Ransi; Stein, Evan; Turner, Traci; Wasserman, Scott M.; NH&MRC Clinical Trials CentrePCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.385, 9965, 2015,pp 331-340